Table 2 Standardised mortality rations (SMR) and absolute excess risks (AER) of 5-year survivors and 10-year survivors of childhood solid tumours according to sex, age at diagnosis, risk group, main diagnostic groups, with corresponding 95% confidence intervals in brackets.

From: Late mortality in survivors of childhood cancer in Hungary

 

Follow-up period 5–10 yrs

Follow-up period beyond 10 yrs

Pyrs

Obs

Exp

SMR

AER

Pyrs

Obs

Exp

SMR

AER

All patients

35,006

151

14.17651

10.651 [9.02–12.493]

39.086 [31.89–46.282]

63,396

145

41.41742

3.501 [2.954–4.12]

16.339 [12.118–20.56]

Males

19,479

79

9.750599

8.102 [6.414–10.098]

35.551 [26.072–45.03]

35,901

86

31.12748

2.763 [2.21–3.412]

15.284 [9.376–21.193]

Females

15,527

72

4.425912

16.268 [12.729–20.487]

43.52 [32.485–54.556]

27,495

59

10.28994

5.734 [4.365–7.396]

17.716 [11.782–23.65]

Age at diagnosis

< 1 yr

4,506

4

3.742565

1.069 [0.291–2.737]

0.571 [− 11.53–12.675]

8,316

15

4.973755

3.016 [1.688–4.974]

12.057 [1.523–22.59]

1–4 yrs

9,723

37

2.361386

15.669 [11.032–21.597]

35.625 [22.978–48.273]

18,803

42

8.454915

4.968 [3.58–6.715]

17.84 [10.436–25.245]

5–9 yrs

8,819

52

2.448218

21.24 [15.863–27.853]

56.188 [39.788–72.587]

16,535

39

10.6865

3.649 [2.833–5.312]

17.123 [8.768–25.479]

10–14 yrs

10,127

51

4.607548

11.069 [8.241–14.553]

45.811 [31.378–60.243]

17,197

41

15.18699

2.7 [1.937–3.662]

15.01 [6.467–23.553]

15–18 yrs

1,831

7

1.016793

6.884 [2.768–14.185]

32.677 [2.369–62.986]

2,545

8

2.115251

3.782 [1.633–7.452]

23.123 [− 1.371–47.617]

Diagnosis period

1973_79

1,798

14

0.787733

17.773 [9.716–29.819]

73.483 [31.564–115.40]

6,880

28

8.773045

3.192 [2.121–4.613]

27.946 [10.671–45.222]

1980_89

8,902

47

4.760055

9.874 [7.255–13.13]

47.45 [31.61–63.29]

24,716

72

18.66532

3.857 [3.018–4.858]

21.579 [14.028–29.13]

1990_99

11,979

50

4.897524

10.209 [7.578–13.46]

37.651 [25.528–49.774]

24,345

37

11.54587

3.205 [2.256–4.417]

10.456 [4.846–16.065]

2000_08

12,327

40

3.731198

10.72 [7.659–14.598]

29.422 [18.908–39.937]

7,455

8

2.43319

3.288 [1.419–6.478]

7.467 [− 1.025–15.959]

CNS tumours

10,791

67

3.646049

18.376 [14.241–23.337]

58.71 [43.444–73.976]

18,734

62

11.46761

5.407 [4.145–6.931]

26.974 [18.006–35.941]

NonCNS tumours

24,215

83

10.53046

7.882 [6.278–9.771]

29.928 [22.1–37.755]

44,662

83

29.94981

2.771 [2.207–3.435]

11.878 [7.214–16.542]

HR

14,934

106

6.440584

16.458 [13.472–19.907]

66.666 [52.749–80.583]

26,501

80

17.29393

4.626 [3.668–5.757]

23.662 [16.367–30.957]

SR

20,072

47

7.735926

6.076 [4.464–8.079]

19.562 [12.337–26.786]

36,895

65

24.12348

2.694 [2.08–3.434]

11.079 [6.064–16.094]

NHL

3,610

6

1.465038

4.095 [1.503–8.914]

13.324 [− 1.51–28.158]

6,322

4

5.347037

0.748 [0.204–1.915]

− 2.131 [− 11.60–7.348]

Hodgkin

4,622

19

1.955754

9.715 [5.849–15.171]

10.406 [− 9.006–29.819]

8,466

32

7.103497

4.505 [3.081–6.359]

29.408 [14.93–43.885]

Astrocytoma

5,289

19

1.699856

11.177 [6.73–17.455]

32.71 [15.849–49.57]

9,725

18

6.185344

2.91 [1.725–4.599]

12.149 [2.237–22.06]

Medullobl/PNET

1,349

19

0.445332

42.665 [25.687–66.626]

137.54 [73.474–201.61]

2,070

5

1.060606

4.714 [1.531–11.002]

19.031 [− 4.279–42.341]

Ependymoma

927

13

0.337685

38.497 [20.498–65.832]

136.59 [59.377–213.81]

1,621

10

1.085432

9.213 [4.418–16.943]

54.994 [14.737–95.252]

CNS other

1,566

6

0.532012

11.278 [4.139–24.547]

34.917 [2.929–66.905]

2,334

8

1.238838

6.458 [2.788–12.724]

28.968 [3.443–54.493]

CNS (no hist)

785

5

0.328857

15.204 [4.937–35.481]

59.505 [1.868–117.14]

1,584

10

1.101806

9.076 [4.352–16.691]

56.175 [14.947–97.404]

NBLI-II

2,126

1

1.219514

0.82 [0.021–4.569]

− 1.033 [− 14.76–12.702]

3,426

1

1.73673

0.576 [0.015–3.208]

− 2.15 [− 11.61–7.314]

NBLIII-IV

1,753

10

0.97946

10.21 [4.896–18.776]

27.438 [− 9.61–64.486]

3,121

10

1.583498

6.315 [3.028–11.614]

26.967 [5.594–48.341]

Retino

1,466

2

0.649988

3.077 [0.373–11.115]

9.209 [− 12.55–30.973]

3,179

4

1.551672

2.578 [0.702–6.6]

7.702 [− 6.825–22.229]

Wilms

3,298

7

1.096119

6.386 [2.568–13.158]

14.584 [− 2.326–31.494]

7,005

5

3.668823

1.363 [0.443–3.18]

1.9 [− 6.338–10.138]

Primhepatic TU

490

1

0.279232

3.581 [0.091–19.953]

14.71 [− 30.53–59.951]

679

0

0.350947

0 [0–10.511]

− 5.169 [− 22.26–11.932]

Softtissuesc

2,283

13

1.011866

12.848 [5.427–19.451]

21.068 [− 11.06–53.205]

4,488

6

3.06223

1.959 [0.719–4.265]

6.546 [− 6.601–19.693]

Osteosarcoma

1,565

8

0.740451

10.804 [4.664–21.289]

46.387 [9.361–83.413]

2,760

11

2.127505

5.17 [2.581–9.251]

32.147 [6.417–57.877]

Ewing

952

10

0.364838

27.409 [13.144–50.407]

101.21 [34.927–167.49]

1,096

3

0.816056

3.676 [0.758–10.744]

19.926 [− 15.00–54.861]

Germ cell

1,113

2

0.438875

4.557 [0.552–16.462]

14.026 [− 13.47–41.528]

2,261

5

1.345693

3.716 [1.206–8.671]

16.162 [− 5.675–37.999]

Carcinoma

1,133

4

0.434283

9.211 [2.51–23.583]

31.471 [− 4.957–67.9]

1,619

3

1.143699

2.623 [0.541–7.666]

11.466 [− 13.17–36.109]

  1. AER absolute excess risk, CNS central nervous system, CNS (no hist) central nervous system tumour with unknown histology, Ewing Ewing sarcoma, exp expected number of deaths, Germ cell germ cell tumours, Hodgkin Hodgkin lymphoma, HR high risk, Medullobl medulloblastoma, NBLI-II neuroblastoma stage I–II, NBLIII-IV neuroblastoma stage III–IV, NHL non-Hodgkin lymphoma, nonCNS tumours tumours located outside the central nervous system, obs observed number of deaths, PNET primitive neuroectodermal tumour, Primhepatic tu primary hepatic tumours, pyrs personyears, Retino retinoblastoma, SMR standardized mortality ratio, Softtissuesc soft tissue sarcoma, SR standard risk, Wilms Wilms tumour.